Alaunos Therapeutics raises $850K via private placement of Series A-2 Convertible Preferred Stock

Alaunos Therapeutics, Inc.

• Aggregate purchase price of $850,000 from accredited investors; offering closed June 24, 2025.
• Each Series A-2 Preferred share priced at $1,000, convertible into common at $4.49 per share.
• Preferred stock carries 10% annual dividend payable in additional Preferred shares.
• Shares issued under Section 4(a)(2) and/or Rule 506(b), are restricted and not registered under Securities Act.
• 1,000 Series A-2 shares designated; 1,639,521 common shares outstanding prior to the offering.